Rhumbline Advisers Acquires 2,787 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Rhumbline Advisers lifted its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 6.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,374 shares of the company’s stock after purchasing an additional 2,787 shares during the quarter. Rhumbline Advisers owned 0.09% of Stoke Therapeutics worth $545,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in STOK. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $124,000. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter worth approximately $160,000. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter worth approximately $192,000. BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after acquiring an additional 71,647 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after acquiring an additional 47,239 shares in the last quarter.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 13,666 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the completion of the transaction, the general counsel now owns 21,476 shares of the company’s stock, valued at $292,288.36. This trade represents a 38.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the transaction, the chief executive officer now directly owns 61,885 shares of the company’s stock, valued at $803,886.15. This represents a 9.88 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,038 shares of company stock worth $307,737. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $8.01 on Friday. The firm has a market cap of $424.27 million, a PE ratio of -3.81 and a beta of 0.99. The firm’s fifty day moving average is $9.85 and its 200-day moving average is $11.83. Stoke Therapeutics, Inc. has a 52 week low of $5.60 and a 52 week high of $17.58.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on STOK shares. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. HC Wainwright increased their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.